---
title: Cell Therapies vs Pluri
slug_a: celltherapies
slug_b: pluri-biotech
site: cdmo
review_signal_gate: closed
canonical_path: /compare/celltherapies/pluri-biotech
generated_by: BioBM Editorial AI
---

# Cell Therapies vs Pluri

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Cell Therapies (celltherapies) is listed for cdmo. GMP contract manufacturer of autologous and allogeneic cell therapies from first-in-human trials through commercial supply, with two decades of experience in CAR-T, mesenchymal stromal cells, TILs, and pluripotent stem cell derivatives. Offers end-to-end cold chain management, process development, quality control analytics, and regulatory consulting across Australia and Asia-Pacific.

Services: 9. Modalities: 2. Indications: 1. Locations: 1. Certifications: 4. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (9).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Pluri (pluri-biotech) is listed for cdmo. Full-service CDMO specializing in cell therapy manufacturing with GMP facilities, proprietary packed-bed expansion technology, and regulatory approvals from FDA, EMA, PMDA, and other key agencies for clinical-stage production.

Services: 11. Modalities: 1. Indications: 0. Locations: 2. Certifications: 3. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (11).

Review summary: Review summary withheld until site-level review gate opens.